[HTML][HTML] Efficacy and safety of vedolizumab in ulcerative colitis and Crohn's disease patients stratified by age
V Yajnik, N Khan, M Dubinsky, J Axler, A James… - Advances in …, 2017 - Springer
Introduction The efficacy and safety of vedolizumab, a gut-selective α 4 β 7 integrin antibody,
were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18–80 years …
were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18–80 years …
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age.
V Yajnik, N Khan, M Dubinsky, J Axler, A James… - Advances in …, 2017 - europepmc.org
Methods Safety and efficacy, including clinical response, clinical remission, and
corticosteroid-free remission, at week 6 and/or 52 were determined post hoc in patients …
corticosteroid-free remission, at week 6 and/or 52 were determined post hoc in patients …
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age
V Yajnik, N Khan, M Dubinsky, J Axler, A James… - 2017 - pubmed.ncbi.nlm.nih.gov
Introduction The efficacy and safety of vedolizumab, a gut-selective α 4 β 7 integrin antibody,
were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18-80 years …
were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18-80 years …
[PDF][PDF] Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age
VYNKM Dubinsky, J Axler, AJBAK Lasch - Adv Ther, 2017 - core.ac.uk
Introduction: The efficacy and safety of vedolizumab, a gut-selective a4b7 integrin antibody,
were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18–80years …
were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18–80years …
[HTML][HTML] Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age
V Yajnik, N Khan, M Dubinsky, J Axler… - Advances in …, 2017 - ncbi.nlm.nih.gov
Methods Safety and efficacy, including clinical response, clinical remission, and
corticosteroid-free remission, at week 6 and/or 52 were determined post hoc in patients …
corticosteroid-free remission, at week 6 and/or 52 were determined post hoc in patients …
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age
V Yajnik, N Khan, M Dubinsky, J Axler… - Advances in …, 2017 - dash.harvard.edu
Introduction: The efficacy and safety of vedolizumab, a gut-selective α4β7 integrin antibody,
were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18–80 years …
were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18–80 years …
[引用][C] Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age
V Yajnik, N Khan, M Dubinsky, J Axler, A James… - Advances in …, 2017 - cir.nii.ac.jp
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified
by Age | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
by Age | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
[PDF][PDF] Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age
VYNKM Dubinsky, J Axler, AJBAK Lasch - Adv Ther, 2017 - researchgate.net
Introduction: The efficacy and safety of vedolizumab, a gut-selective a4b7 integrin antibody,
were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18–80years …
were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18–80years …
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age
V Yajnik, N Khan, M Dubinsky, J Axler, A James… - Advances in …, 2017 - infona.pl
Introduction The efficacy and safety of vedolizumab, a gut-selective α4β7 integrin antibody,
were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18–80 years …
were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18–80 years …
[PDF][PDF] Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age
VYNKM Dubinsky, J Axler, AJBAK Lasch - Adv Ther, 2017 - academia.edu
Introduction: The efficacy and safety of vedolizumab, a gut-selective a4b7 integrin antibody,
were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18–80years …
were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18–80years …